VRTX : Summary for Vertex Pharmaceuticals Incorpor - Yahoo Finance

U.S. Markets close in 4 hrs 20 mins

Vertex Pharmaceuticals Incorporated (VRTX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
108.66+0.65 (+0.60%)
As of 11:40AM EDT. Market open.
People also watch
ALXNREGNBMRNINCYBIIB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close108.01
Open107.88
Bid108.24 x 300
Ask108.32 x 300
Day's Range106.52 - 109.73
52 Week Range71.46 - 111.88
Volume1,434,011
Avg. Volume1,831,924
Market Cap26.99B
Beta2.08
PE Ratio (TTM)-236.21
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedia27 minutes ago

    Corbus Pharma Add-on Drug Clears Mid-Stage Study

    Corbus's anti-inflammatory drug, anabasum, met the primary endpoint for safety and tolerability in Phase 2.

  • No. 5-Ranked Biotech Bolts Higher On Drug Results
    Investor's Business Daily37 minutes ago

    No. 5-Ranked Biotech Bolts Higher On Drug Results

    Vertex Pharma saw its IBD SmartSelect Composite Rating rise to 97 Thursday, up from 92 the day before.

  • Barrons.com1 hour ago

    Vertex: 'Calling Results Strong Does Not Make Them So'

    Yesterday, we at Barron's took a victory lap after Vertex Pharmaceuticals (VRTX) soared 20% after releasing data from its cystic fibrosis drug trial that was deemed a success. While many sell-side analysts seem to think it was, but not H.C. Wainwright's Andrew Fein and Emile Yu, who write that "calling results strong does not make them so." They explain why: In yesterday’s investor call following results from the EVOLVE and EXPAND studies of the tez/iva (661/770) combo, management highlighted their view that “the 4% is different than the 2.8%”.